Invasive fungal infections in allogeneic and autologous stem cell transplant recipients: a single-center study of 166 transplanted patients

被引:79
作者
Post, M. J.
Lass-Floerl, C.
Gastl, G.
Nachbaur, D.
机构
[1] Innsbruck Med Univ, Clin Div Hematol & Oncol, A-6020 Innsbruck, Austria
[2] Innsbruck Med Univ, Dept Microbiol, Innsbruck, Austria
关键词
stem cell transplantation; invasive fungal infection; invasive aspergillosis; invasive candidiasis; VERSUS-HOST-DISEASE; MARROW TRANSPLANTATION; RISK-FACTORS; FLUCONAZOLE PROPHYLAXIS; GRAFT; ASPERGILLOSIS; BLOOD; COMPLICATIONS; EPIDEMIOLOGY; CYCLOSPORINE;
D O I
10.1111/j.1399-3062.2007.00219.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives. Invasive fungal infections (IFIs) remain a major cause of infection-related morbidity and mortality following hematopoietic stem cell transplantation (HSCT). Patients anal methods. We retrospectively analyzed the incidence of IFIs in 166 patients undergoing either allogeneic or autologous HSCTat our institution between January 2000 and December 2003. Results. Incidence of invasive aspergillosis (IA) and invasive candidiasis among [CI]) and 3% (1-9%,95% CI), respectively. Duration of neutropenia and reduced-intensity conditioning were the only risk factors for IA in the multivariate model. Patients with IA had significantly reduced overall survival (8% versus 56%, P = 0.01) due to higher transplant-related mortality (63% versus 31%, P= 0.03). Following autologous HSCT, incidence of IA and invasive candidiasis Nvas 8% (4-19 /0, 95% CI) and 2% (0.2-11%, 95% CI), respectively. Duration of neutropenia was the only risk factor for the development of IA following autologous HSCT Overall survival of autologous HSCT recipients with IAwas similar to that of patients without IA. Seventeen percent of autologous HSCT recipients were colonized with Candida species. Compared with non-colonized patients these patients had significantly reduced overall survival (72% versus 23%, P = 0.004), due to increased treatment-related mortality (23% versus 9%, P= 0.02). Conclusion. Diagnosis of IA following allogeneic HSCTand Candida colonization in the setting of autologous HSCTdefines patient populations with poor outcome but primarily not as a result of the fungal pathogen. Regarding the incidence of IA, duration of neutropenia is the main risk factor, and dose-reduced conditioning is an additional risk factor for the development of IA following allogeneic HSCT, probably owing to increased recipient age in this patient cohort, requiring further studies in this transplantation setting.
引用
收藏
页码:189 / 195
页数:7
相关论文
共 35 条
  • [1] Infectious complications of implantable ports and Hickman catheters in paediatric haematology-oncology patients
    Adler, A
    Yaniv, I
    Steinberg, R
    Solter, E
    Samra, Z
    Stein, J
    Levy, I
    [J]. JOURNAL OF HOSPITAL INFECTION, 2006, 62 (03) : 358 - 365
  • [2] Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus
    Ascioglu, S
    Rex, JH
    de Pauw, B
    Bennett, JE
    Bille, J
    Crokaert, F
    Denning, DW
    Donnelly, JP
    Edwards, JE
    Erjavec, Z
    Fiere, D
    Lortholary, O
    Maertens, J
    Meis, JF
    Patterson, TF
    Ritter, J
    Selleslag, D
    Shah, PM
    Stevens, DA
    Walsh, TJ
    [J]. CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) : 7 - 14
  • [3] Infectious complications the year after autologous bone marrow transplantation or peripheral stem cell transplantation for treatment of breast cancer
    Barton, TD
    Collis, T
    Stadtmauer, E
    Schuster, MG
    [J]. CLINICAL INFECTIOUS DISEASES, 2001, 32 (03) : 391 - 395
  • [4] Extending postgrafting cyclosporine decreases the risk of severe graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation
    Burroughs, L
    Mielcarek, M
    Leisenring, W
    Sandmaier, BM
    Maloney, DG
    Baron, F
    Martin, PJ
    Flowers, MED
    Forman, SJ
    Chauncey, TR
    Bruno, B
    Storb, R
    [J]. TRANSPLANTATION, 2006, 81 (06) : 818 - 825
  • [5] Antifungal prophylaxis with azole derivatives
    Castagnola, E
    Machetti, M
    Bucci, B
    Viscoli, C
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2004, 10 : 86 - 95
  • [6] Oral candidiasis in hematopoietic cell transplantation patients: An outcome-based analysis
    Epstein, JB
    Hancock, PJ
    Nantel, S
    [J]. ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY, 2003, 96 (02): : 154 - 163
  • [7] Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning
    Fukuda, T
    Boeckh, M
    Carter, RA
    Sandmaier, BM
    Maris, MB
    Maloney, DG
    Martin, PJ
    Storb, RF
    Marr, KA
    [J]. BLOOD, 2003, 102 (03) : 827 - 833
  • [8] CLINICAL MANIFESTATIONS OF GRAFT VERSUS HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONORS
    GLUCKSBERG, H
    STORB, R
    FEFER, A
    BUCKNER, CD
    NEIMAN, PE
    CLIFT, RA
    LERNER, KG
    THOMAS, ED
    [J]. TRANSPLANTATION, 1974, 18 (04) : 295 - 304
  • [9] GOOLEY TA, 1999, STAR MED, V18, P659
  • [10] Zygomycosis (mucormycosis): emerging clinical importance and new treatments
    Greenberg, RN
    Scott, LJ
    Vaughn, HH
    Ribes, JA
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2004, 17 (06) : 517 - 525